Cyberonics may have to scale back its projections for fiscal 2013, as the Centers for Medicare and Medicaid Services has again declined to cover the company's brain-stimulating implant for treatment-resistant depression.
For years patients from depression have been cycled through one drug after the next, a hit-and-miss approach that also reflects the poor odds of success in clinical development. But now investigators say that a trial of a well-known anesthetic often used illicitly in the club scene has real potential in the fight against depression.
Danish pharmaceutical group Lundbeck on Wednesday reported that its investigational depression drug vortioxetine improved a number of cognitive functions in preclinical animal models.
A protein identified by researchers at King's College London could be central to alleviating the long-term detrimental effect that stress has on cells, opening up a possible new approach to treating depression.
As more and more data supports brain stimulation therapy to treat pain and depression, Cervel Neurotech has hauled in $14.1 million in venture funding to develop its noninvasive device.
Alkermes has a shot at offering a new option for treating depression in patients who don't respond to existing drugs. The company revealed positive preliminary data from a Phase II study of ALKS 5461, an opioid-receptor targeting drug, which the biotech player now aims to march into pivotal development.
Lundbeck has rolled out a fresh set of positive data on its new antidepressant Brintellix (vortioxetine/Lu AA21004), this time offering up some head-to-head results to help position the drug in the marketplace.
Larger-than usual amounts of quinolinic acid appear to be a viable biomarker for severe depression, Australian researchers have concluded, and they're using it as the basis for a blood test now under development to gauge high suicide risk.
A group of investigators at New York University's medical school has launched an ambitious effort to define a group of biomarkers that could be used to quickly and easily diagnose complex cases of post-traumatic stress disorder, traumatic brain injury and eventually even depression.
While devicemakers like Israel's Brainsway are commercializing magnetic brain stimulation therapies for depression, a new study found that direct currents applied to the cranium can boost the effectiveness of antidepressants.